Stanley Laman Group Ltd. acquired a new position in shares of LogicBio Therapeutics Inc (NASDAQ:LOGC) in the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm acquired 19,530 shares of the company’s stock, valued at approximately $254,000. Stanley Laman Group Ltd. owned approximately 0.09% of LogicBio Therapeutics at the end of the most recent quarter.
Several other hedge funds and other institutional investors have also recently bought and sold shares of LOGC. Deutsche Bank AG bought a new position in LogicBio Therapeutics in the fourth quarter valued at approximately $115,000. Geode Capital Management LLC bought a new position in LogicBio Therapeutics in the fourth quarter valued at approximately $626,000. Northern Trust Corp bought a new position in LogicBio Therapeutics in the fourth quarter valued at approximately $873,000. Finally, BlackRock Inc. bought a new position in LogicBio Therapeutics in the fourth quarter valued at approximately $3,927,000. 56.03% of the stock is owned by institutional investors.
LOGC has been the topic of a number of recent research reports. Roth Capital initiated coverage on shares of LogicBio Therapeutics in a research note on Wednesday, May 1st. They issued a “buy” rating and a $26.00 price objective on the stock. ValuEngine raised shares of LogicBio Therapeutics from a “hold” rating to a “buy” rating in a research note on Thursday, August 1st. Zacks Investment Research raised shares of LogicBio Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, August 10th. Finally, Chardan Capital reaffirmed a “buy” rating and issued a $20.00 price objective on shares of LogicBio Therapeutics in a research note on Thursday. One research analyst has rated the stock with a hold rating and five have given a buy rating to the company. LogicBio Therapeutics has a consensus rating of “Buy” and an average target price of $24.00.
LogicBio Therapeutics (NASDAQ:LOGC) last announced its quarterly earnings results on Tuesday, August 13th. The company reported ($0.45) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.41) by ($0.04). As a group, sell-side analysts expect that LogicBio Therapeutics Inc will post -1.59 EPS for the current year.
LogicBio Therapeutics Company Profile
LogicBio Therapeutics, Inc, a genome editing company, focuses on developing medicines to treat rare diseases in patients with unmet medical need using GeneRide technology platform. The GeneRide technology is designed to integrate corrective genes into a patient's genome to provide a therapeutic effect.
Featured Story: Cost of Goods Sold (COGS)
Receive News & Ratings for LogicBio Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LogicBio Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.